Author Archives: Ana Pamplona, PhD

Distinguishing PAH and PH May Have Gotten Easier

A new study identifies the hemodynamic variables that distinguish patients with idiopathic pulmonary arterial hypertension (PAH) from those with isolated post-capillary pulmonary hypertension (PH), a finding that will help to diagnose and treat  more accurately and effectively patients with these disease subsets. The study, “Hemodynamic thresholds for pre-capillary pulmonary…

Selexipag Reduces Risk of Morbidity/Mortality Episodes in Pulmonary Arterial Hypertension

During the American College of Cardiology (ACC) Congress held this March (14-16) in San Diego, data from the pivotal Selexipag (Uptravi®) Phase III GRIPHON study was shared in an oral presentation. The presentation, entitled “Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study” was presented by Dr. Vallerie V.

New Pulmonary Fibrosis Diagnostic Tool Would Be Faster & Quicker

A new study highlighting a diagnostic test based on peripheral blood for idiopathic pulmonary fibrosis entitled “Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood” was recently published in BMC Genomics by Eric B Meltzer at Vanderbilt University Medical Center. In this study, the…

Researchers Determine eRAP As Viable PAH Prognosticator

A new study on pulmonary arterial hypertension (PAH) entitled “Echocardiographic Assessment of Estimated Right Atrial Pressure and Size Predicts Mortality in Pulmonary Arterial Hypertension” was published in Chest by Dr. Christopher Austin, part of Dr. Brian Shapiro’s group from Division of Cardiovascular Disease at the…

Antidepressant Use Linked To IPAH in New Study

A recent study, entitled “The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension,” which is set to be published in The Canadian Journal of Cardiology by Dr. Benjamin D. Fox, of the Centre for Clinical Epidemiology, Jewish General Hospital, and collaborators, addresses the…

New Omentin Study Sheds Light On PAH

Omentin, an adipocyte-derived cytokine, is a potential novel candidate to treat obesity-related cardiovascular disease. Dr. Kyosuke Kazama and colleagues from the School of Veterinary Medicine, Kitasato University, Japan, have shown for the first time that long term treatment for 14 days with omentin inhibits vascular structural remodeling and abnormal contractile…